Literature DB >> 22371131

Gynecological cancer: First-line bevacizumab for ovarian cancer--new standard of care?

Susana Banerjee, Stan B Kaye.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22371131     DOI： 10.1038/nrclinonc.2012.28

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  6 in total

1.  What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?

Authors:  Ernest S Han; Bradley J Monk
Journal:  Gynecol Oncol       Date:  2007-04       Impact factor: 5.482

2.  Targeted therapies: bevacizumab--has it reached its final resting place?

Authors:  David J Kerr; Annie M Young
Journal:  Nat Rev Clin Oncol       Date:  2011-03-08       Impact factor: 66.675

Review 3.  The role of targeted therapy in ovarian cancer.

Authors:  Susana Banerjee; Stan Kaye
Journal:  Eur J Cancer       Date:  2011-09       Impact factor: 9.162

4.  A phase 3 trial of bevacizumab in ovarian cancer.

Authors:  Timothy J Perren; Ann Marie Swart; Jacobus Pfisterer; Jonathan A Ledermann; Eric Pujade-Lauraine; Gunnar Kristensen; Mark S Carey; Philip Beale; Andrés Cervantes; Christian Kurzeder; Andreas du Bois; Jalid Sehouli; Rainer Kimmig; Anne Stähle; Fiona Collinson; Sharadah Essapen; Charlie Gourley; Alain Lortholary; Frédéric Selle; Mansoor R Mirza; Arto Leminen; Marie Plante; Dan Stark; Wendi Qian; Mahesh K B Parmar; Amit M Oza
Journal:  N Engl J Med       Date:  2011-12-29       Impact factor: 91.245

5.  Incorporation of bevacizumab in the primary treatment of ovarian cancer.

Authors:  Robert A Burger; Mark F Brady; Michael A Bookman; Gini F Fleming; Bradley J Monk; Helen Huang; Robert S Mannel; Howard D Homesley; Jeffrey Fowler; Benjamin E Greer; Matthew Boente; Michael J Birrer; Sharon X Liang
Journal:  N Engl J Med       Date:  2011-12-29       Impact factor: 91.245

6.  OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.

Authors:  Carol Aghajanian; Stephanie V Blank; Barbara A Goff; Patricia L Judson; Michael G Teneriello; Amreen Husain; Mika A Sovak; Jing Yi; Lawrence R Nycum
Journal:  J Clin Oncol       Date:  2012-04-23       Impact factor: 44.544
  6 in total
  4 in total

1.  Gynaecological cancer: OCEANS' three: the ovarian job.

Authors:  M Teresa Villanueva
Journal:  Nat Rev Clin Oncol       Date:  2012-05-15       Impact factor: 66.675

Review 2.  Brain metastasis: new opportunities to tackle therapeutic resistance.

Authors:  Joan Seoane; Leticia De Mattos-Arruda
Journal:  Mol Oncol       Date:  2014-06-02       Impact factor: 6.603

3.  Peritoneal tumor spread in serous ovarian cancer-epithelial mesenchymal status and outcome.

Authors:  Katharina Auer; Anna Bachmayr-Heyda; Stefanie Aust; Nyamdelger Sukhbaatar; Agnes Teresa Reiner; Christoph Grimm; Reinhard Horvat; Robert Zeillinger; Dietmar Pils
Journal:  Oncotarget       Date:  2015-07-10

4.  Retreatment with bevacizumab in patients with gynecologic malignancy is associated with clinical response and does not increase morbidity.

Authors:  Robin A Laskey; Scott D Richard; Ashlee L Smith; Jeff F Lin; Tiffany L Beck; Jamie L Lesnock; Joseph L Kelley; Alexander B Olawaiye; Paniti Sukumvanich; Thomas C Krivak
Journal:  Onco Targets Ther       Date:  2014-03-21       Impact factor: 4.147
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.